Sajid Fatima, Ahmed Taha, Baz Maher A, Anstead Michael I
Pulmonology, University of Kentucky, Lexington, USA.
Hospital Medicine, University of Kentucky, Lexington, USA.
Cureus. 2021 Aug 13;13(8):e17152. doi: 10.7759/cureus.17152. eCollection 2021 Aug.
Coronavirus disease 2019 (COVID-19) is currently a significant cause of acute respiratory failure worldwide, leading to irreversible fibrotic lung disease. In patients with persistent respiratory failure after acute COVID-19 infection, lung transplant is an emerging option. Here, we have presented a case where the patient required venovenous extracorporeal membrane oxygenation (VV-ECMO) support for 33 days until a bilateral lung transplant was performed on day 71 after the initial COVID-19 infection. The early outcomes have been favorable. Currently, no guidelines exist for an acceptable time period after initial COVID-19 infection, duration of negative COVID polymerase chain reaction (PCR) testing, or negative Vero cell culture in the setting of persistent positive COVID PCR testing before listing for a lung transplant. Due to a lack of standardized guidelines, this patient was not listed for a lung transplant until the COVID-19 PCRs came negative on days 47 and 49 after the infection.
2019冠状病毒病（COVID-19）目前是全球急性呼吸衰竭的一个重要病因，可导致不可逆的肺纤维化疾病。在急性COVID-19感染后出现持续性呼吸衰竭的患者中，肺移植是一种新出现的选择。在此，我们报告了一例患者，该患者在初次COVID-19感染后需要静脉-静脉体外膜肺氧合（VV-ECMO）支持33天，直到第71天进行了双侧肺移植。早期结果良好。目前，对于初次COVID-19感染后的可接受时间段、COVID聚合酶链反应（PCR）检测阴性的持续时间，或在持续COVID PCR检测呈阳性的情况下，在列入肺移植名单之前Vero细胞培养阴性的持续时间，尚无指南。由于缺乏标准化指南，该患者直到感染后第47天和第49天COVID-19 PCR检测呈阴性才被列入肺移植名单。
